Business

BusinessNEWSVIRAL NEWS

The United States pharmaceutical industry entered a new phase of government intervention after President Donald Trump announced a landmark agreement with Regeneron Pharmaceuticals. The deal, centered on the Trump drug price deal Regeneron, marks the final agreement in a broader initiative involving 17 major pharmaceutical companies under the administration’s “Most Favored Nation” (MFN) pricing strategy.

The announcement, made on April 23, 2026, signals a continued push by the White House to reduce prescription drug costs

Read More
BusinessNEWSVIRAL NEWS

The Intel Earnings 2026 report has sent shockwaves across the tech and financial world, signaling a powerful turnaround for the semiconductor giant after years of uncertainty. Under CEO Lip-Bu Tan, Intel is not just recovering—it is redefining its identity by returning to what leadership calls its “paranoid” engineering-driven roots.

This renewed mindset appears to be working. The company delivered stronger-than-expected quarterly results, sparking a surge in its stock and

Read More
BusinessNEWSVIRAL NEWS

The Trump drug price deal has emerged as one of the most significant healthcare policy developments in 2026, drawing both praise and criticism across the political spectrum. Announced as part of a broader push to reduce prescription drug costs, the agreement between former President Donald Trump’s administration and pharmaceutical giant Regeneron signals a renewed effort to tackle one of America’s most persistent economic concerns: high healthcare costs.

The deal, unveiled on April 23, 2026, aims to lower drug prices through a combination of government negotiation, market incentives,

Read More